Rare Biologics

Rare Biologics Services

Orphan-Scale. High-Impact. Human-Centered.

At Mika Biologics, we know that not every biologic is destined for blockbuster scale. Some are designed for rare diseases that affect only a handful of patients worldwide. Others are niche biologics, orphan enzymes, or experimental therapies serving specialized clinical needs. Yet these molecules are no less vital—in fact, they often carry profound human impact.

Most CDMOs focus on high-volume biologics, where economies of scale maximize revenue. Rare biologics fall through the cracks: too small for Catalent or Lonza to prioritize, too complex for commodity microbial houses to execute. Innovators developing these therapies face a double bind: life-changing science but no manufacturing partner willing to scale with them.

Mika Biologics was built to solve this. Our rare biologics platform specializes in orphan-scale, small-batch GMP manufacturing, ensuring that therapies for rare diseases, specialty indications, and niche biologics can move forward with the same quality, rigor, and care as blockbuster drugs.

Mika Biologics, CDMO for Microbial projects

What Are Rare Biologics?

Rare biologics are therapeutic proteins, enzymes, or biologic products developed for:

  • Rare Diseases (Orphan Indications)
    • Affect fewer than 200,000 people in the US (per FDA definition).
    • Often involve enzymes, cytokines, or niche immune proteins.
  • Orphan-Scale Clinical Programs
    • Clinical trials requiring grams, not kilograms of biologics.
    • First-in-human studies, early-phase manufacturing.
  • Niche Therapeutic Biologics
    • Lysosomal enzymes, diagnostic proteins, or orphan cytokines.
    • Specialty biologics not prioritized by large CDMOs.
  • Low-Volume Commercial Supply
    • Therapies where the annual market requires small but consistent GMP batches.

For patients with rare diseases, these biologics are not niche—they are everything.

Why Rare Biologics Matter

The global market for orphan drugs exceeds $200B annually and is one of the fastest-growing segments in pharma. Yet manufacturing bottlenecks remain the single biggest challenge for innovators.

  1. Human Impact – Each therapy can transform or save lives in communities often overlooked by mainstream medicine.
  2. Regulatory Incentives – Orphan drug designation provides accelerated pathways, exclusivity, and tax benefits.
  3. Scientific Innovation – Many rare biologics pioneer new mechanisms of action, paving the way for broader classes of drugs.
  4. Commercial Potential – Small patient numbers, but high per-patient value makes rare biologics a sustainable business model.

Despite this, most large CDMOs de-prioritize orphan-scale clients, focusing on blockbuster deals. Mika Biologics fills this gap.

Our Rare Biologics Services

We provide end-to-end support for rare biologics programs, designed to handle small volumes with high precision.

1. Orphan-Scale GMP Manufacturing

Our facilities are tailored for flexible, small-batch GMP runs:

  • Batch Sizes – From sub-50 L pilot runs to 200–2000 L fermentors.
  • GMP-Ready – ISO-aligned, FDA-registered, EU-compliant.
  • Multi-Use Facilities – Stainless steel and single-use bioreactors.
  • Agile Scheduling – Designed to prioritize smaller clients without long queue times.

Whether you need grams for preclinical studies or kilograms for Phase I/II trials, Mika is equipped to deliver.

2. Rare Enzyme Manufacturing

Many rare diseases stem from enzyme deficiencies, requiring therapeutic enzyme replacement. We specialize in:

  • Lysosomal Enzymes – For metabolic and storage disorders.
  • Orphan Cytokines – ILs, GFs, or modulators with limited markets.
  • Diagnostic Enzymes – Specialty proteins for rare diagnostics.

Capabilities:

  • Microbial (E. coli, yeast, fungi) or cell-free expression.
  • Refolding workflows for active enzyme recovery.
  • Bioactivity validation with functional assays.
  • GMP supply in orphan-scale volumes.

3. Clinical Trial Supply

We provide end-to-end manufacturing for early-phase trials:

  • Phase I/II Batch Manufacturing – GMP runs sized for early trials.
  • Clinical Packaging – Vials, lyophilized formats, custom formulations.
  • Regulatory Documentation – IND/CTA support, comparability studies.
  • Accelerated Timelines – Agile project planning for fast-moving trials.

4. Orphan Drug Regulatory Alignment

Rare biologics require specialized regulatory support. We help clients:

  • Secure Orphan Drug Designation (FDA, EMA).
  • Navigate Accelerated Approval pathways.
  • Build CMC strategies tailored to small-batch production.
  • Prepare for regulatory inspections and filings.

5. Pilot-Scale & Preclinical Support

Not every project starts with GMP. For preclinical programs, we offer:

  • Pilot Plant Runs – 1–50 L scale, optimized for speed and data generation.
  • Comparability Studies – Bridging pilot to GMP batches.
  • Analytical Characterization – ELISA, HPLC, mass spectrometry, bioassays.
  • Stability Testing – Shelf-life and stress studies.

This ensures smooth tech transfer when programs advance to GMP.

Why Choose Mika for Rare Biologics?

Most CDMOs are designed for high-volume programs. Mika was designed differently.

1. Rare Is Normal for Us

We don’t treat rare biologics as exceptions—we treat them as our core focus.

2. Orphan-Scale Agility

Our facilities are flexible, designed for grams-to-kilograms, not just tons.

3. Technical Mastery of “Difficult” Proteins

Our microbial-first expertise allows us to express cytokines, enzymes, and niche proteins that others avoid.

4. Regulatory Fluency

We understand the special pathways and incentives for rare biologics.

5. Patient-Centered Philosophy

Every rare biologic represents patients waiting for therapies that may not exist otherwise. For us, this is personal.

Technical Infrastructure

Mika Biologics offers state-of-the-art infrastructure optimized for rare biologics:

  • Fermentation – 1–2000 L in-house, 20,000 L with partners.
  • Downstream Processing – centrifugation, TFF, chromatography, lyophilization.
  • Analytics – bioassays, ELISA, HPLC/UHPLC, mass spectrometry.
  • Quality – ISO, FDA, EU compliance.
  • Digital Systems – electronic batch records, PAT integration.

Applications & Case Studies

  • Rare Disease Foundation – Partnered with Mika to produce a lysosomal enzyme for a metabolic disorder, enabling Phase I trials.
  • Biotech Startup – Orphan cytokine manufactured at 50 L scale, with GMP comparability data bridging to Phase II.
  • Diagnostics Innovator – Specialty enzyme produced in small GMP batches for rare diagnostic kits.
  • Global Health NGO – Small-batch GMP interferon for an ultra-rare viral program.

The Future of Rare Biologics at Mika

We see rare biologics not as niche, but as a future growth engine for biotech. Our roadmap includes:

  • Distributed Orphan GMP Facilities – modular units for flexible small-batch runs.
  • AI-Driven Rare Protein Design – predictive folding, solubility, and refolding for orphan enzymes.
  • Patient-Centered Partnerships – co-development models with patient advocacy groups.
  • Expanded Regulatory Pathways – alignment with emerging orphan biologics incentives worldwide.

Closing Statement

Rare biologics represent the soul of biotechnology: therapies designed not for millions, but for the few who need them most. They demand specialized platforms, flexible facilities, and partners who care as much about impact as scale.

At Mika Biologics, we make rare biologics possible. By specializing in orphan-scale, small-batch GMP manufacturing, we ensure that therapies for rare diseases and niche biologics have the same rigor, reproducibility, and global readiness as blockbuster biologics.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.\

Email our sales team at info@mikabiologics.com